Cardiomyopathy: US funding opportunity

Information concerning a recent call for proposals on cardiomyopathy from the "Peer Reviewed Medical Research Program" (part of the US Department of Defense)

Within this topic area, they are particularly interested in the following (but will consider others):

- Development of novel therapeutic approaches for primary and secondary cardiomyopathies.
- Strategies to identify risk factors associated with the development of cardiomyopathy (i.e., genetic, lifestyle, exposure) in the civilian and/or military populations.
- Research to improve the understanding of the pathophysiology of cardiomyopathies.
- Improvement of noninvasive diagnostic techniques for primary and secondary cardiomyopathies.
- Research on the multiple etiologies of cardiomyopathy (e.g., hypertension, ischemia, hemochromatosis, sleep apnea, radiation therapy, medications, smallpox vaccine, infections).

Researchers in Switzerland are eligible to apply and the Grants Office provides support. The call is open, with several types of awards available (see attached overview). The "Discovery Award" and the "Investigator-Initiated Research Award" are probably the most suitable. Both require a very short pre-application, due on March 28 and March 14, respectively.

For further information, please contact Leah Witton at the Grants Office (leah.witton@research.unibe.ch).

Fiscal Year 2019 Department of Defense Peer Reviewed Medical Research Program (PRMRP) Reference Table of Award Mechanisms and Submission Requirements

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadlines
Discovery Award Go to: Program Announcement General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-19-PRMRP-DA	Postdoctoral fellow or clinical fellow (or equivalent) and above	 Supports the exploration of a highly innovative new concept or untested theory in the Topic Area(s) of interest. Not intended to support the logical progression of an already established line of questioning. Clinical trials will not be funded. Reviewers will be blinded to the identity of the Principal Investigator (PI), collaborator(s), and their organization(s). 	Maximum funding of \$200,000 for direct costs (plus indirect costs) Maximum period of performance is 2 years	Pre-Application (Letter of Intent): March 28, 2019 5:00 p.m. Eastern time (ET) Application: April 11, 2019 11:59 p.m. ET
Clinical Trial Award Go to: Program Announcement General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-19-PRMRP-CTA	Assistant Professor level or above (or equivalent)	 Supports the rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the Topic Area(s) of interest. Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials. Investigational New Drug or Investigational Device Exemption applications, if needed, should be approved by the Food and Drug Administration (FDA) prior to the PRMRP application submission deadline. A copy of the FDA Acknowledgement letter and meeting minutes, if applicable, should be submitted with the full application. If the trial will be conducted internationally, a copy of the relevant national regulatory agency approval should be submitted with the full application. Preproposal submission is required; application submission is by invitation only. 	No maximum funding limit; requested funding must be justifiable and appropriate for the scope of work proposed; budget will be considered during preapplication screening and will be a scored full application criterion Maximum period of performance is 4 years	Pre-Application (Preproposal): March 14, 2019 5:00 p.m. ET Application: July 2, 2019 11:59 p.m. ET

Fiscal Year 2019 Department of Defense Peer Reviewed Medical Research Program (PRMRP) Reference Table of Award Mechanisms and Submission Requirements

Focused Program Award Go to: Program Announcement General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-19-PRMRP-FPA	Lead PI: Full Professor level or above (or equivalent) Project Leads: Assistant Professor level or above (or equivalent)	 Supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal in the Topic Area(s) of interest. Projects should work together to answer critical questions, resolve differing hypotheses, and translate laboratory findings to clinical applications. Projects may range from exploratory/hypothesis-developing through small-scale clinical trials that together will address the overarching goal/question. Research team of highly qualified, multidisciplinary project leaders should be led by a PI with demonstrated success in directing large, focused projects. Preproposal submission is required; application submission is by invitation only. 	Maximum funding of \$7.2 million for direct costs (plus indirect costs) Maximum period of performance is 4 years	Pre-Application (Preproposal): March 14, 2019 5:00 p.m. ET Application: July 2, 2019 11:59 p.m. ET
Investigator-Initiated Research Award Go to:	Assistant Professor level or above (or equivalent)	 Supports research that will make an original and important contribution to the field of research and/or patient care in the Topic Area(s) of interest. Partnering PI Option available. Clinical trials will not be funded. Preproposal submission is required; application submission is by invitation only. 	Maximum funding of \$1.2 million for direct costs (plus indirect costs); \$1.5 million for direct costs (plus indirect costs) for applications including a Partnering PI Option Maximum period of performance is 3 years	Pre-Application (Preproposal) March 14, 2019 5:00 p.m. ET Application: July 10, 2019 11:59 p.m. ET
Technology/Therapeutic Development Award Go to: Program Announcement General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-19-PRMRP-TTDA	Assistant Professor level or above (or equivalent)	 Supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, or quality of life in the Topic Area(s) of interest. Product-oriented (e.g., device, drug, clinical guidelines). The product(s) to be developed may be a tangible item, such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product. Clinical trials will not be funded. Preproposal submission is required; application submission is by invitation only. 	Maximum funding of \$3 million for direct costs (plus indirect costs) Maximum period of performance is 3 years	Pre-Application (Preproposal): March 14, 2019 5:00 p.m. ET Application: July 10, 2019 11:59 p.m. ET